| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Not a targeted therapeutic in the classical sense; acts as a creatine analog, potentially interacting with creatine kinase and cellular energy metabolism pathways. Creatine kinase is the enzyme that catalyzes the reversible transfer of a phosphate group from phosphocreatine to ADP to generate ATP, and from ATP to creatine to regenerate phosphocreatine. Creatinol, as an N-ethyl analogue of creatine, may be recognized by creatine transporters (SLC6A8) and may serve as a substrate for creatine kinase, although with different kinetic properties compared to creatine. By modulating the phosphocreatine energy shuttle, creatinol may influence cellular ATP availability, particularly in tissues with high energy demands such as skeletal muscle, cardiac muscle, and brain.
|
|---|---|
| ln Vitro |
Creatinol hemisulfate serves as a creatine analog in biochemical assays. It may influence cellular energy metabolism by modulating creatine kinase activity or cellular uptake via creatine transporters. In vitro, creatinol may compete with creatine for uptake by creatine transporters and may affect the phosphocreatine/creatine ratio in cells. The N-ethyl substitution distinguishes creatinol from creatine and may alter its interaction with creatine kinase and transporters, providing a tool for studying the structure-activity relationships of creatine analogs. Detailed in vitro activity data (e.g., IC50, EC50) are not extensively reported in the available literature.
|
| ln Vivo |
Creatinol hemisulfate is investigated in animal models for conditions such as muscle wasting and neurodegenerative diseases. As a creatine analog, it may support physical performance and energy metabolism via creatine-related pathways. In vivo, creatinol may be taken up by creatine transporters and may contribute to the phosphocreatine pool, potentially providing neuroprotective or muscle-protective effects. However, detailed in vivo efficacy data (e.g., effects on muscle strength, motor function, or survival in disease models) are not extensively reported in the available literature.
|
| Enzyme Assay |
In vitro creatine kinase activity assays are performed using recombinant or tissue-extracted creatine kinase incubated with varying concentrations of creatinol hemisulfate and ATP. Enzyme activity is measured by monitoring NADH oxidation (in coupled assays with pyruvate kinase and lactate dehydrogenase) or phosphate production spectrophotometrically. The ability of creatinol to serve as a substrate for creatine kinase or to inhibit creatine kinase activity can be assessed by comparing the reaction kinetics with those of creatine. Creatine transporter uptake assays can be performed using cells expressing the creatine transporter SLC6A8, with radiolabeled or fluorescently labeled creatine analogs to measure uptake.
|
| Cell Assay |
Muscle cell lines (e.g., C2C12 myotubes) or neuronal cell lines are treated with creatinol hemisulfate at various concentrations. Cellular ATP levels are measured using luciferase-based assays (CellTiter-Glo) to assess the effects on energy metabolism. Creatine uptake via creatine transporters is measured using radiolabeled creatine (e.g., 14C-creatine) in the presence of varying concentrations of creatinol to determine competitive inhibition. Cell viability is assessed using standard assays (MTT, CCK-8) to evaluate cytotoxicity. The effects of creatinol on cellular differentiation (e.g., myotube formation in C2C12 cells) may also be assessed.
|
| Animal Protocol |
Rodent models of muscle wasting (e.g., denervation-induced atrophy, cachexia models) or neurodegenerative diseases (e.g., ALS, Huntington's disease) are administered creatinol hemisulfate via oral gavage or intraperitoneal injection. Muscle strength is assessed using grip strength tests or rotarod performance. Motor function is evaluated using open field tests, balance beam, or other behavioral assays. Tissue ATP levels and phosphocreatine/creatine ratios are measured in muscle and brain tissue to assess the effects on energy metabolism. Detailed in vivo efficacy data for creatinol hemisulfate are not extensively reported in the available literature.
|
| ADME/Pharmacokinetics |
Predicted to have similar pharmacokinetic properties to creatine: moderate oral bioavailability (creatine is absorbed from the gastrointestinal tract with ~70% bioavailability), distribution into muscle and brain via creatine transporters (SLC6A8), and renal clearance. The N-ethyl substitution may alter the affinity for creatine transporters and creatine kinase, potentially affecting tissue distribution and metabolism. Standard pharmacokinetic parameters (Cmax, Tmax, AUC, t1/2) are evaluated in rodents. Creatinol is expected to be excreted primarily in urine as unchanged drug or as the metabolite creatinine.
|
| Toxicity/Toxicokinetics |
Creatinol hemisulfate is a creatine analog with an expected safety profile similar to creatine supplementation. Creatine is generally well-tolerated at doses up to 20 g/day, with common side effects including weight gain, gastrointestinal discomfort, and muscle cramping. High doses may cause renal effects in susceptible individuals. Creatinol, as a creatine analog, may have similar safety considerations. Standard toxicology studies are typically required for therapeutic development. As a research compound, detailed toxicology data are not publicly available.
|
| References | |
| Additional Infomation |
Creatinol hemisulfate is a research-grade compound used in biochemistry and physiology studies. Molecular formula: C4H11N3O·½H2SO4 (or C8H24N6O6S), molecular weight: 166.18. Solubility: water soluble at 100 mg/mL; insoluble in DMSO. Storage: 4°C, protect from light. Synonyms: muscle alcohol sulfate, N-(2-hydroxyethyl)-N-methylguanidine sulfate (2:1), Creatinol hemisulfate. It is the N-ethyl analogue of creatine and can be used for various research studies. For research use only, not for human therapeutic use.
|
| Molecular Formula |
C4H11N3O.1/2H2O4S
|
|---|---|
| Molecular Weight |
166.18
|
| Exact Mass |
332.148
|
| CAS # |
50648-53-8
|
| PubChem CID |
45381533
|
| Appearance |
White to off-white solid powder
|
| Boiling Point |
446.1ºC at 760 mmHg
|
| Flash Point |
223.6ºC
|
| Hydrogen Bond Donor Count |
8
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
21
|
| Complexity |
165
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CN(CCO)C(=N)N.CN(CCO)C(=N)N.OS(=O)(=O)O
|
| InChi Key |
UXBBURPYFRPXAL-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/2C4H11N3O.H2O4S/c2*1-7(2-3-8)4(5)6;1-5(2,3)4/h2*8H,2-3H2,1H3,(H3,5,6);(H2,1,2,3,4)
|
| Chemical Name |
1-(2-hydroxyethyl)-1-methylguanidine;sulfuric acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O :~100 mg/mL (~601.76 mM; with sonication)
DMSO :< 1 mg/mL (insoluble or slightly soluble) |
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.0176 mL | 30.0879 mL | 60.1757 mL | |
| 5 mM | 1.2035 mL | 6.0176 mL | 12.0351 mL | |
| 10 mM | 0.6018 mL | 3.0088 mL | 6.0176 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Link: https://clinicaltrials.gov/ct2/show/NCT01444170
Conditions:Injury|InflammationProducts are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
